Immuron Ltd (IMC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immuron Ltd (IMC) has a cash flow conversion efficiency ratio of -0.189x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.48 Million ≈ $-1.75 Million USD) by net assets (AU$13.08 Million ≈ $9.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Immuron Ltd market capitalisation for the company's overall valuation and market capitalisation.
Immuron Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Immuron Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immuron Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immuron Ltd ranked by their cash flow conversion efficiency. See IMC operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cielo Waste Solutions Corp
V:CMC
|
0.632x |
|
Bram Indus
TA:BRAM
|
0.069x |
|
Federal International Holdings Bhd
KLSE:8605
|
-0.049x |
|
Cazaly Resources Ltd
AU:CAZ
|
-0.048x |
|
U-BX Technology Ltd.
NASDAQ:UBXG
|
-0.017x |
|
LABORATORIO FARMAC.ERFO
F:RK7
|
N/A |
|
Morien Resources Corp
V:MOX
|
1.454x |
|
Daekyo Co Ltd
KO:019685
|
0.035x |
Annual Cash Flow Conversion Efficiency for Immuron Ltd (2001–2025)
The table below shows the annual cash flow conversion efficiency of Immuron Ltd from 2001 to 2025. View Immuron Ltd (IMC) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$8.07 Million ≈ $5.71 Million |
AU$-6.14 Million ≈ $-4.34 Million |
-0.761x | -64.39% |
| 2024-06-30 | AU$12.71 Million ≈ $8.99 Million |
AU$-5.88 Million ≈ $-4.16 Million |
-0.463x | -264.71% |
| 2023-06-30 | AU$19.62 Million ≈ $13.88 Million |
AU$-2.49 Million ≈ $-1.76 Million |
-0.127x | +6.13% |
| 2022-06-30 | AU$23.18 Million ≈ $16.40 Million |
AU$-3.13 Million ≈ $-2.22 Million |
-0.135x | +14.30% |
| 2021-06-30 | AU$25.90 Million ≈ $18.32 Million |
AU$-4.08 Million ≈ $-2.89 Million |
-0.158x | +71.88% |
| 2020-06-30 | AU$5.64 Million ≈ $3.99 Million |
AU$-3.16 Million ≈ $-2.24 Million |
-0.561x | -129.19% |
| 2019-06-30 | AU$7.35 Million ≈ $5.20 Million |
AU$-1.80 Million ≈ $-1.27 Million |
-0.245x | +41.08% |
| 2018-06-30 | AU$8.44 Million ≈ $5.97 Million |
AU$-3.50 Million ≈ $-2.48 Million |
-0.415x | +61.17% |
| 2017-06-30 | AU$6.57 Million ≈ $4.65 Million |
AU$-7.03 Million ≈ $-4.97 Million |
-1.069x | -2.42% |
| 2016-06-30 | AU$4.94 Million ≈ $3.50 Million |
AU$-5.16 Million ≈ $-3.65 Million |
-1.044x | -66.26% |
| 2015-06-30 | AU$4.81 Million ≈ $3.40 Million |
AU$-3.02 Million ≈ $-2.14 Million |
-0.628x | -60.80% |
| 2014-06-30 | AU$6.79 Million ≈ $4.80 Million |
AU$-2.65 Million ≈ $-1.88 Million |
-0.391x | +97.23% |
| 2013-06-30 | AU$144.99K ≈ $102.59K |
AU$-2.05 Million ≈ $-1.45 Million |
-14.108x | -1074.35% |
| 2012-06-30 | AU$2.05 Million ≈ $1.45 Million |
AU$-2.46 Million ≈ $-1.74 Million |
-1.201x | -5.67% |
| 2011-06-30 | AU$1.73 Million ≈ $1.23 Million |
AU$-1.97 Million ≈ $-1.39 Million |
-1.137x | -69.19% |
| 2010-06-30 | AU$3.36 Million ≈ $2.38 Million |
AU$-2.26 Million ≈ $-1.60 Million |
-0.672x | -105.99% |
| 2009-06-30 | AU$-184.87K ≈ $-130.81K |
AU$-2.07 Million ≈ $-1.47 Million |
11.209x | +699.89% |
| 2008-06-30 | AU$1.11 Million ≈ $785.58K |
AU$-2.07 Million ≈ $-1.47 Million |
-1.868x | -23.80% |
| 2007-06-30 | AU$1.98 Million ≈ $1.40 Million |
AU$-2.99 Million ≈ $-2.12 Million |
-1.509x | -181.71% |
| 2006-06-30 | AU$5.24 Million ≈ $3.71 Million |
AU$-2.81 Million ≈ $-1.99 Million |
-0.536x | -112.46% |
| 2005-06-30 | AU$6.96 Million ≈ $4.93 Million |
AU$-1.76 Million ≈ $-1.24 Million |
-0.252x | +16.78% |
| 2004-06-30 | AU$4.08 Million ≈ $2.89 Million |
AU$-1.24 Million ≈ $-874.24K |
-0.303x | +0.21% |
| 2002-06-30 | AU$6.32 Million ≈ $4.47 Million |
AU$-1.92 Million ≈ $-1.36 Million |
-0.304x | -36.77% |
| 2001-06-30 | AU$7.48 Million ≈ $5.29 Million |
AU$-1.66 Million ≈ $-1.17 Million |
-0.222x | -- |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more